Pediatrix Medical Group reported adjusted EBITDA of $85 million for the quarter and narrowed its full-year 2026 adjusted EBITDA outlook to $290 to $300 million. Same unit revenue was positive, with equal contributions from volume and pricing. The company repurchased just over 3 million shares in the quarter, bringing total buybacks since August of 2025 to 10 million shares.
MD · Pediatrix Medical Group, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $29.94
- Open
- $30.41
- Day range
- $29.73–30.93
- 52-week closing range
- $18.82–32.80
- Average volume, 30 days
- 686K
- Short interest
- 3.5M · 4.5% of shares · 5.0 days
- Short volume, last session
- 68%
- Last earnings
- Oct 29, 2026
- Latest filing
- 10-Q · Oct 29
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Pediatrix Medical Group's net income fell to $47.0 million for the three months ended September 30, 2026, from $71.7 million a year earlier, while Adjusted EBITDA was $85.5 million versus $87.3 million. Working capital dropped to $148.3 million as the Term A Loan, maturing in February 2027, was reclassified to current debt. Stock repurchases totaled $147.2 million in the nine months ended September 30, 2026.
Pediatrix Medical Group reported third-quarter 2026 diluted earnings of $0.59 per share on net revenue of $501.4 million. Net income was $47.0 million, and Adjusted EPS was $0.72. The company expects full year 2026 Adjusted EBITDA of $290 million to $300 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 4, 2026TL;DR. Pediatrix reported Q2 2026 adjusted EBITDA of $76 million and reaffirmed its full-year 2026 adjusted EBITDA guidance of $280–$300 million, noting stable payor mix, strong RCM collections, and rising acuity, while same-unit patient volumes declined 2% and NICU days fell 3%.
- + Generated $76 million in Q2 adjusted EBITDA, in line with expectations
- + Reaffirmed full-year 2026 adjusted EBITDA guidance of $280–$300 million
- + Repurchased nearly 2 million shares in Q2, bringing total buybacks since August 2025 to 7 million shares and reducing share count to 81 million from 87 million
- + Strong balance sheet with $289 million cash, ~1x leverage, and $126 million operating cash flow supports growth and capital returns
- − Same-unit patient service volumes declined 2%, with NICU days down 3%
- − Management expects full-year 2026 volumes to be flat to slightly down
- − RCM collections tailwind expected to dissipate in the second half of 2026
- − Q2 operating cash flow of $126 million fell from $138 million in the prior-year quarter
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $134.6M | the six months ended June 30, 2026 | — |
| Adjusted EPS non-GAAP | $1.07 | the six months ended June 30, 2026 | — |
| Adjusted income and diluted EPS non-GAAP | $1.07 | Six Months Ended June 30, 2026 | — |
| Contracted managed care | 72% | the three months ended June 30, 2026 filing | — |
| Government | 23% | the three months ended June 30, 2026 filing | — |
| Growth in non-same unit activity | 2.1% | the three months ended June 30, 2026 | — |
| Growth in same-unit revenue | 1.9% | the three months ended June 30, 2026 | — |
| Hospital-based patient services volume change | -2.8% | the three months ended June 30, 2026 | — |
| Neonatal intensive care unit (NICU) days change | -3.2% | the three months ended June 30, 2026 | — |
| Office-based patient services volume change | -1.2% | the three months ended June 30, 2026 | — |
| Other third-parties | 4% | the three months ended June 30, 2026 filing | — |
| Percentage of services reimbursed by commercial and other non-government payors change | 135 | the 2026 second quarter | — |
| Same-unit net revenue increase | 1.9% | the three months ended June 30, 2026 filing | — |
| Same-unit revenue attributable to patient volume | -2.1% | the 2026 second quarter | — |
| Same-unit revenue from net reimbursement-related factors | 4% | the 2026 second quarter | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MD
this stock
Pediatrix Medical Group, Inc.
|
$2.34B | +40.0% | -4.9% | 16.3 | 4.5% |
|
HCA
HCA Healthcare, Inc.
|
$96.16B | -1.4% | +7.1% | 15.3 | 2.3% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$32.17B | -0.3% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$20.98B | +32.6% | +0.9% | 7.6 | 2.2% |
|
EHC
Encompass Health Corp
|
$12.98B | +24.6% | +10.5% | 20.7 | 3.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 29, 2026
- This year
- 15
Pediatrix Medical Group reported third-quarter 2026 diluted earnings of $0.59 per share on net revenue of $501.4 million. Net income was $47.0 million, and Adjusted EPS was $0.72. The company expects full year 2026 Adjusted EBITDA of $290 million to $300 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MD | -4.7% | +1.3% | +38.5% | +0.4% | +40.0% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +0.8% | +7.6% | +44.1% | +5.7% | +35.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.